SynthesisEnvironment international2025
Incidence and mortality of acute aflatoxicosis: A systematic review.
Synthesis in Environment international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Intracellular artificial DNA receptor-loaded gelated cells for aflatoxin theranostics.Nature communications · 2026Article
- Multi-omics characterization of Saccharomyces boulardii in the biocontrol of Aspergillus flavus.Archives of microbiology · 2026Article
- Maternal Aflatoxin Exposure, Birth Outcomes, and Infant Growth in Uganda.The American journal of tropical medicine and hygiene · 2026Article
- Distinct Phenotype and Secondary Metabolite Profile Mark a DominantJournal of fungi (Basel, Switzerland) · 2026Article
- Integrated metabolomic and proteomic analyses reveal global reprogramming of oocyte metabolism following AFB1 exposure.Cell communication and signaling : CCS · 2026Article
- Mapping Global Research Trends on Aflatoxin M1 in Dairy Products: An Integrative Review of Prevalence, Toxicology, and Control Approaches.Foods (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAflatoxins are mycotoxins produced by Aspergillus fungi in crops intended for food and feed. Acute exposure to high levels of aflatoxin B1, one of the most toxic mycotoxins, can result in severe poisoning, defined as acute aflatoxicosis, which manifests as acute hepatic failure followed by death in severe cases. Currently global burden estimates of acute aflatoxicosis are lacking - in contrast to burden estimates of chronic exposure - making it difficult to implement and prioritize risk management strategies in the prevention and control of aflatoxin exposure.
aimThis systematic review assessed global evidence on the incidence and mortality of acute aflatoxicosis from 1990 to 2023. While symptomology & disease duration was also examined, it served as a secondary outcome to provide additional clinical context. SEARCH STRATEGY AND ELIGIBILITY: A structured search was conducted in PubMed, Web of Science, Embase, Scopus, INASP and grey literature. Studies were imported into Covidence for review. STUDY SELECTION AND EXTRACTION: Two independent reviewers screened and extracted titles, abstracts, and full texts. Eligible studies included all human studies.
resultsFrom 11,539 references, 9 studies were included. Heterogeneity existed in study design, region, age of the study population and aflatoxin analysis. Number of cases ranged from 1 to 317, with aflatoxin concentrations varying widely, i.e. between 10 and 51,100 µg/kg in food, 36 and 209,000 pg/mg albumin in serum, and 19 and 18,521 pg/g in tissue. Only one outbreak provided sufficient data to estimate an attack rate of 8 cases per 100,000. Mortality ranged from 16.2 to 76.5 %, affecting children under 15 and adults over 40 most severely. Common symptoms included vomiting (77-100 %), jaundice (88-100 %), and abdominal pain (8-87 %). The risk of bias was generally low.
conclusionThis review shows that acute aflatoxicosis remains a significant public health burden, especially among vulnerable groups in African countries, although the variability in studies and lack of standardized reporting make burden estimation difficult, highlighting the need for better warning systems and standardized reporting, despite challenges with infrastructure and resources in affected areas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.